Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation

Abstract

Objective. To explore the predictive value of magnetic resonance imaging (MRI) with serum lectin-reactive alpha-fetoprotein (AFP-L3) for liver cancer recurrence after percutaneous radiofrequency ablation (RFA). Methods. This study included 94 liver cancer patients admitted for RFA treatment and 82 healthy subjects. MRI was performed to record the apparent diffusion coefficient (ADC). The serum concentrations of AFP-L3 were quantified in all participants. The correlation of the AFP-L3 serum level and ADC value with clinical efficacy following RFA was analyzed. Moreover, the prognostic factors affecting liver cancer recurrence were analyzed, as well as the predictive effect of the ADC value and AFP-L3 on liver cancer recurrence. Results. The serum AFP-L3 level was higher in liver cancer patients than the healthy controls with a lower ADC value. Besides, the patients with tumor residuals had lower ADC values and higher serum AFP-L3 levels than those with complete ablated tumor. The combined detection of the ADC value and serum AFP-L3 level had a sensitivity of 87.50% and a specificity of 87.18% for diagnosing complete ablation after RFA treatment. The number of tumor nodules, tumor diameter, AFP, AFP-L3, and the presence of liver cirrhosis are all independent risk factors for liver cancer recurrence within one year. Meanwhile, the combined detection of the ADC value and serum AFP-L3 level had a good predictive effect on liver cancer recurrence with the sensitivity of 92.86% and a specificity of 69.62%. Conclusion. The ADC values combined with serum AFP-L3 detection had good predictive effects on complete ablation and recurrence of liver cancer after RFA treatment.

Association between the systemic immune inflammation index and recurrence or metastasis after interventional therapy in patients with primary liver cancer- a retrospective cohort study

“…Moreover, Alphafetoprotein (AFP) is the most commonly used biological indicator in patients with PLC, which has a high value in distinguishing PLC from metastatic liver cancer (6)(7)(8) and also has some value in identifying recurrence or metastasis after treatment of PLC. However, the timeliness of AFP is poor: after treatment, patients with markedly elevated AFP often already have recurrence or metastasis and therefore AFP cannot be used as an early predictor of the risk of recurrence or metastasis after PLC TACE or radiofrequency ablation therapy (9,10). The systemic immune inflammation index can reflect the inflammatory state and immune function status of patients with malignant tumors and has been used to evaluate the prognosis of patients with a variety of malignant tumors (11)(12)(13)(14)(15), but there is a lack of relevant studies in evaluating the predicting value of systemic immune inflammation index in patients with PLC after TACE or radiofrequency ablation therapy.…”

Retracted: Predictive Value of MRI with Serum Lectin‐Reactive Alpha‐Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation

“…This article has been retracted by Hindawi following an investigation undertaken by the publisher [ 1 ]. This investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process: Discrepancies in scope Discrepancies in the description of the research reported Discrepancies between the availability of data and the research described Inappropriate citations Incoherent, meaningless and/or irrelevant content included in the article Peer-review manipulation …”

“…Tis article has been retracted by Hindawi following an investigation undertaken by the publisher [1]. Tis investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process:…”